The burgeoning field of precision oncology just saw a significant capital injection, with 1Cell.Ai Inc. announcing it has raised $16.0M in a Series A funding round. The diagnostics company is focused on developing first-in-class, circulating tumor cell (CTC)-based, single-cell multi-omics lab developed tests. These advanced tests are aimed at applications in clinical cancer care and early-stage clinical trials for biotech and pharma companies.
1Cell.Ai Inc. operates as a joint venture, bringing together Actorius Innovations and Research Pvt Ltd, a prominent provider of CTC Tests in India, and Indx.ai, a Silicon Valley-based software company specializing in multi-omics biomarker data analytics.

















